AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02157311
Drug: Four consecutive days on treatment and 3 days off
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
Trial: NCT03108534
Drug: CHF1535 NEXThaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment
Trial: NCT03108534
Drug: CHF1535 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment
Trial: NCT03108534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment
Trial: NCT02451748
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: some patients are on 1000 mg/day of naproxen
Trial: NCT02451748
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
Trial: NCT03696121
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
Trial: NCT01415505
Drug: Nebivolol, Valsartan and Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
Trial: NCT00014573
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02544984
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Trial: NCT02544984
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Trial: NCT00408993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every day (QD), by mouth (PO)
Trial: NCT02696850
Drug: Saline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
Trial: NCT00171587
Drug: PTK787/ZK 222584 (vatalanib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03738865
Drug: G-Pen
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pro-Pen-G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Trial: NCT02488486
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02298218
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
Trial: NCT00581945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to ACZ885 administered via intravenous infusion.
Trial: NCT02669030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group
Trial: NCT02048761
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
Trial: NCT04321837
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate
Trial: NCT00767000
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 tablets three times daily
Trial: NCT00767000
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-0941 three times daily
Trial: NCT02912533
Drug: JR-131
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02528201
Drug: Celecoxib 200 milligrams
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 milligrams once a day
Trial: NCT02528201
Drug: Celecoxib 400 milligrams
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 milligrams once a day
Trial: NCT02528201
Drug: diclofenac 50 milligrams
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 50 milligrams three times a day
Trial: NCT01194115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo representing standard of care
Trial: NCT00126451
Drug: Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02065440
Drug: Rhinoebastel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
Trial: NCT02065440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
Trial: NCT01116245
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
Trial: NCT02060396
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of Adiro 100 mg will be administered daily orally for 7 days.
Trial: NCT00052065
Drug: TLK286
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00692939
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mobilization
Trial: NCT04894864
Drug: Opioid-Based Anesthesia-Analgesia Strategy
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
Trial: NCT04894864
Drug: Opioid-free Anesthesia-Analgesia Strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
Trial: NCT02833831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered.
Trial: NCT00425438
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
Trial: NCT00425438
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
Trial: NCT00425438
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
Trial: NCT02760407
Drug: Placebo q2w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Trial: NCT00673673
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
Trial: NCT01462292
Drug: GSK2402968 3mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 2 doses of GSK2402968
Trial: NCT01462292
Drug: GSK2402968 6 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 2 doses of GSK2402968
Trial: NCT01462292
Drug: Placebo to match GSK2402968 3 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01462292
Drug: Placebo to match GSK2402968 6 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT00510692
Drug: Eicosapentanoic Acid (EPA)
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 500mg EPA capsules twice daily for 6 months
Trial: NCT00510692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500mg placebo capsules twice daily for 6 months
Trial: NCT03156153
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Trial: NCT03156153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Trial: NCT00945191
Drug: CS-1008
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
Trial: NCT00997685
Drug: Capecitabine plus oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles
Trial: NCT01475292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via a nebuliser once daily for 14 days
Trial: NCT03399110
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2
Trial: NCT03048097
Drug: Fluorodeoxyglucose
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
Trial: NCT00721526
Drug: disulfiram plus lorazepam
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
Trial: NCT00353704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of saccharose (placebo) was administered about one hour before surgery
Trial: NCT00221845
Drug: ACE Inhibition
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Trial: NCT00221845
Drug: Intensified Blood Pressure Control
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Trial: NCT00221845
Drug: Add-on Angiotensin Receptor Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Trial: NCT02613572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00458250
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00458250
Drug: CAMPATH-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00458250
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03587324
Drug: Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)
Trial: NCT01303627
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
Trial: NCT01159496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, once daily for 14 days
Trial: NCT01376752
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
Trial: NCT02504645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100463
Drug: 0.1% Uracil Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily lotion to prevent HFS
Trial: NCT00003498
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01513850
Drug: Hepabulin IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V.
Trial: NCT01620463
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
Trial: NCT04478097
Drug: CKD-330 Tab. and D086 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT04478097
Drug: CKD-333 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT01259544
Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of powder form dissolved in one cup of tap water prior to breath test
Trial: NCT01259544
Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
Trial: NCT00872898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, once daily, oral administration.
Trial: NCT04544826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.
Trial: NCT00681317
Drug: AZD6280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03963895
Drug: AB002 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
Trial: NCT03963895
Drug: AB002 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
Trial: NCT03963895
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered on Day 1 as a single intravenous infusion
Trial: NCT00606424
Drug: 20 mCi dose for a 50 kg individual of [F-18]HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
Trial: NCT00958919
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml
Trial: NCT00795600
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin NPH once daily plus insulin aspart at mealtime
Trial: NCT00736996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablet daily for 6 months
Trial: NCT03660683
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablets
Trial: NCT04504045
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
Trial: NCT02647359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Trial: NCT02736539
Drug: CBS 2004 (galacto-oligosaccharides)
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS 2004 active treatment
Trial: NCT02736539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT03310541
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
Trial: NCT03050476
Drug: RESCAP®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Trial: NCT03050476
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Trial: NCT00490425
Drug: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04574544
Drug: Zinc Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
Trial: NCT00093145
Drug: Herceptin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT00723177
Drug: Placebo (PCB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
Trial: NCT00001481
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Trial: NCT00748436
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (placebo tablet + placebo tablet) BID per os 12 weeks
Trial: NCT04287920
Drug: Acomprosate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
Trial: NCT01069783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator once daily for the duration of the trial
Trial: NCT01435577
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum 12 administrations over 48 hours
Trial: NCT00680316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
Trial: NCT01876121
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03328897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of placebo
Trial: NCT00812292
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05413187
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil and Chlorophyl
Trial: NCT03189914
Drug: RX-3117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX-3117 will be administered orally in combination with Abraxane.